ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Upadacitinib Meets Primary, All Ranked Secondary Endpoints in Ulcerative Colitis Study
December 10, 2020AbbVie announced positive results from the Phase 3 induction study, U-ACHIEVE, which showed upadacitinib (45 mg, once daily) met the primary endpoint of clinical remission (per Adapted Mayo Score) at week 8, as well as all ranked secondary endpoints ...
Pharma Sources Insight January 2025
